Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 14M | 16M | 0 | 0 | 0 |
| Gross Profit | 11M | 16M | 0 | 0 | 0 |
| Operating Income | -84M | -89M | -82M | -123M | -70M |
| EBITDA | -80M | -66M | -80M | -123M | -69M |
| Net Income | -80M | -77M | -74M | -121M | -76M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.03
+6.84% today
1Y Change
+44.63%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pyxis Oncology, Inc. (PYXS) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $2.03 and up 44.6% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -14.2%, EPS growth of +3.0%, a dividend yield of 0.0%. What stands out right now is revenue -14.2%, EPS +3.0%, free cash flow -9.7% with operating margin -609.2% and ROIC -117.1%. Valuation sits in the middle of the pack at price/sales 7.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PYXS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PYXS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PYXS Max Drawdown
-80.15%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PYXS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$76.0M
+37.1% YoY
Free Cash Flow
-$35.9M
+62.5% YoY
Revenue Growth
-14.2%
EPS Growth
+3.0%
Gross Margin
103.1%
Net Margin
-574.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 14M | 16M | 0 | 0 | 0 |
| Gross Profit | 11M | 16M | 0 | 0 | 0 |
| Operating Income | -84M | -89M | -82M | -123M | -70M |
| EBITDA | -80M | -66M | -80M | -123M | -69M |
| Net Income | -80M | -77M | -74M | -121M | -76M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15M | 19M | 10M | 179M | 275M |
| Total Assets | 92M | 157M | 174M | 211M | 280M |
| Total Liabilities | 38M | 36M | 48M | 51M | 19M |
| Shareholder Equity | 53M | 121M | 126M | 161M | 261M |
| Total Debt | 19M | 20M | 21M | 19M | 165K |
| Net Debt | 3M | 727K | 12M | -160M | -275M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
35M
+60.5% YoY
Capital Expenditures
540K
+91.6% YoY
Free Cash Flow
36M
+62.5% YoY
Key ratios
Gross Margin
103.1%
Operating Margin
-609.2%
Net Margin
-574.5%
ROE
-101.8%
Debt / Equity
0.35x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.